URC 102

Drug Profile

URC 102

Alternative Names: URC-102

Latest Information Update: 16 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Chugai Pharmaceutical; JW Pharmaceutical
  • Developer JW Pharmaceutical
  • Class Antigouts
  • Mechanism of Action SLC22A12 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout

Most Recent Events

  • 13 Dec 2016 URC 102 is still in phase II trials for Gout in South Korea (PO) (JW pharmaceutical pipeline, December 2016)
  • 01 Aug 2016 JW Pharmaceutical completes a phase II trial for Gout in South Korea (NCT02557126)
  • 25 Sep 2015 JW Pharmaceutical plans a phase II trial for Gout in South Korea (NCT02557126)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top